NCT03704688

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.

Conditions

• Non Small Cell Lung Cancer
• KRAS Gene Mutation

Interventions

Type	Name	Description
DRUG	Trametinib 0.5 mg	0.5mg PO q daily
DRUG	Trametinib 1 MG	1.0 mg PO q daily
DRUG	Trametinib 1.5 MG	1.5mg PO q daily
DRUG	Trametinib 2 mg	2 mg PO q daily
DRUG	Ponatinib 15 MG	15mg PO q daily
DRUG	Ponatinib 30 MG	30mg PO q daily

Timeline

• Start date: 2018-10-09
• Primary completion: 2022-02-04
• Completion: 2022-02-04
• First posted: 2018-10-15
• Last updated: 2025-05-16
• Results posted: 2023-09-21

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study